Nitazoxanide in NASH-Induced Fibrosis
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models.
NTZ is currently being evaluated in an investigator-initiated proof-of-concept clinical trial for the potential treatment of NASH-induced significant liver fibrosis.
For more information, go to clinical trials.gov.
*NTZ is not approved for use in NASH.
-
Most popular related searches
Customer reviews
No reviews were found for Nitazoxanide in NASH-Induced Fibrosis. Be the first to review!